# Selank Dosage in Research: Routes, Half-Life, and Study Context > Selank dosage as studied: the research doses, intranasal route, half-life, and study durations. Research context only — never a human recommendation. The research doses, the intranasal route, the very short half-life, and the multi-week clinical courses — reported as study facts, never as a protocol for people. ## The short version Here is the plain truth about **Selank** dosage: this page reports what researchers used in studies, and nothing more. It is not a how-to, there is no recommended human amount here, and you won't find one — that would cross the line into medical advice this site doesn't give. In animal work, doses are usually measured per kilogram of body weight (for example, 300 µg/kg was used in one rat brain-gene study) [4]. The Russian clinical formulation is a 0.15% liquid given as nose drops over courses of a few weeks. The peptide itself clears the body fast — its intact half-life is on the order of minutes — though its breakdown products may keep the effect going a while longer. If you're reading for the research facts, that's exactly what follows. If you want safety context, that lives on [the effects page](/effects). ## Selank dosage in the research Across the published work, **Selank dosage** is a study variable, not a consumer instruction. Animal studies frequently use roughly 100–300 µg/kg given intranasally or systemically; the rat GABA gene-expression study used a single 300 µg/kg dose, which shifted the expression of 45 genes at one hour [4]. In humans, the Russian clinical formulation is a 0.15% aqueous intranasal solution applied as nasal drops, and anxiety-disorder trials administered intranasal Selank over multi-week courses (on the order of two to three weeks) as an alternative or adjunct to benzodiazepine therapy [6][16]. These are reported here as documented study parameters. This site gives no human dose and makes no recommendation. ## Selank half life **Selank half life** is short — and that's central to how it behaves. The intact heptapeptide is rapidly metabolized, with a reported plasma half-life on the order of minutes. That sounds like a problem, but the design accounts for it: the C-terminal Pro-Gly-Pro extension dramatically slows enzymatic degradation relative to native tuftsin, and the metabolites are thought to retain biological activity, which is proposed to stretch the functional duration of effect well beyond the parent peptide's measured lifetime. The honest caveat: no rigorously validated human pharmacokinetic profile for Selank has been published in mainstream Western literature, so the "active metabolite extends the effect" rationale is mechanistically plausible but not precisely quantified [6]. The short half-life also fits the very common user report that a single dose feels short-lived. ## Selank nasal spray The **Selank nasal spray** (or nasal drops) is the primary clinical route in Russia, delivered as that 0.15% intranasal solution [6]. The nose-to-brain route is attractive because it can deliver a peptide centrally while bypassing the gut, where peptides are quickly destroyed. A mouse study comparing intranasal versus intraperitoneal administration found comparable central pharmacological effects via the intranasal route, supporting it as a viable delivery method in research [15]. Beyond intranasal, rodent studies have also used intraperitoneal, subcutaneous, and intravenous routes for pharmacokinetic and behavioral work. ## Selank peptide protocol When people search for a **Selank peptide protocol**, they're usually looking for a daily-versus-situational schedule. The research record only documents study designs, not consumer protocols: human trials used multi-week intranasal courses for anxiety disorders [6][16], while animal work used single or repeated dosing depending on the model. Selank is typically supplied lyophilized (freeze-dried) for research, and reconstituted solutions are kept refrigerated for stability. This site documents those study parameters and stability notes; it does not publish a human protocol, dose, or schedule, because Selank is not an approved medicine and this is editorial commentary, not medical guidance. ## Why dosing data stays in the research lane Selank is not FDA-approved, and the dosing evidence is single-region and preclinical-heavy [6]. There is no validated, independently replicated human dosing standard outside the Russian clinical work, and the human pharmacokinetics are poorly characterized [6]. That's why every number on this page is attributed to a specific study and framed as a study parameter. For the full safety reasoning — including interaction and long-term unknowns — see [Selank effects](/effects), and for the complete sources, the [references](/references). --- A friendly, honestly-cited digest of the Selank research — bright on the page, careful with the evidence.